Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SATRALIZUMAB-MWGE for Multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where SATRALIZUMAB-MWGE was used for Multiple sclerosis.

Most Reported Side Effects for SATRALIZUMAB-MWGE

Side Effect Reports % Deaths Hosp.
Neuromyelitis optica spectrum disorder 181 16.3% 3 67
Off label use 87 7.8% 2 37
Urinary tract infection 87 7.8% 3 58
Pneumonia 64 5.8% 4 54
Covid-19 47 4.2% 5 25
No adverse event 47 4.2% 0 0
Fatigue 41 3.7% 0 10
Headache 36 3.2% 1 10
Pain 36 3.2% 0 15
Arthralgia 31 2.8% 0 5
Hypoaesthesia 30 2.7% 0 11
Nausea 27 2.4% 0 8
Sepsis 24 2.2% 3 21
Pyrexia 23 2.1% 1 11
Asthenia 22 2.0% 2 11

Other Indications for SATRALIZUMAB-MWGE

Neuromyelitis optica spectrum disorder (994) Product used for unknown indication (84) Demyelination (15) Myelitis (11) Myelin oligodendrocyte glycoprotein antibody-associated disease (5)

Other Drugs Used for Multiple sclerosis

DIMETHYL (78,567) NATALIZUMAB (56,733) INTERFERON BETA-1A (56,475) FINGOLIMOD (43,123) TERIFLUNOMIDE (29,963) DALFAMPRIDINE (28,787) GLATIRAMER (27,144) OCRELIZUMAB (15,501) OFATUMUMAB (11,816) PEGINTERFERON BETA-1A (11,105)

Related Pages

SATRALIZUMAB-MWGE Full Profile All Multiple sclerosis Drugs SATRALIZUMAB-MWGE Demographics SATRALIZUMAB-MWGE Timeline